MALT1 (Mucosa-associated Lymphoid Tissue Lymphoma Translocation Protein 1, MALT Lymphoma-associated Translocation, Paracaspase, MLT), DKFZp434L132) (PE)

Antibodies / Antibodies-Apoptosis

4°C Do Not Freeze

Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with R-Phycoerythrin (PE).

Full length human MALT1, aa1-813 (NP_776216.1).

MALT1/Paracaspase (MALT1) was independently identified as a member of the human paracaspase family and an interacting partner of B-cell lymphoma. MALT1 is a caspase-like protein that contains an N-terminal death domain, two Ig-like domains, and a C-terminal caspase-like domain. It binds to Bcl10 through its Ig-like domains and cooperates with Bcl10-activate NF-kappaB. MALT1 is thought to play an important role in NF-kappaB signaling by enchancing NF-kappaB activation through interaction with Bcl10. Interaction between MALT1 and Bcl10 mediates IKK activation in vitro through facilitatiing the ubiquitination of NEMO by the ubiquitin-conjugating enzyme UBC13. Four recurrent chromosomal translocations have been described in non-Hodgkin B-cell lymphoma of the mucosa-associated lymphoid issue (MALT) type. Two of them, t(14; 18)(q32; q21) and t(11; 18)(q21; q21), are found in 30% to 50% of extranodal MALT lymphomas. The first translocation juxtaposes the MALT1 gene to the IgH promoter region, resulting in the deregulation of MALT1 expression, whereas the second translocation generates a fusion between MALT1 and the inhibitor of apoptosis gene API2 (cIAP2/HIAP1). The other two much rarer translocations, t(1; 14)(p22; q32)and t(1; 2)(p22; p12), target Bcl10 gene on the short arm of chromosome 1. Translocations involving Bcl10 and MALT1 may lead to elevated NF-kappaB activity in MALT B-cell lymphoma. Two alternatively spliced transcript variants encoding different isoforms (a and b) have been described for the MALT1 gene. Human MALT1 isoform a is an aa protein of 824aa, and human MALT1 isoform b is an aa protein of 813aa.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

AA Sequence:
MSLLGDPLQALPPSAAPTGPLLAPPAGATLNRLREPLLRRLSELLDQAPEGRGWRRLAELAGSRGRLRLSCLDLEQCSLKVLEPEGSPSLCLLKLMGEKGCTVTELSDFLQAMEHTEVLQLLSPPGIKITVNPESKAVLAGQFVKLCCRATGHPFVQYQWFKMNKEIPNGNTSELIFNAVHVKDAGFYVCRVNNNFTFEFSQWSQLDVCDIPESFQRSVDGVSESKLQICVEPTSQKLMPGSTLVLQCVAVGSPIPHYQWFKNELPLTHETKKLYMVPYVDLEHQGTYWCHVYNDRDSQDSKKVEIIIDELNNLGHPDNKEQTTDQPLAKDKVALLIGNMNYREHPKLKAPLVDVYELTNLLRQLDFKVVSLLDLTEYEMRNAVDEFLLLLDKGVYGLLYYAGHGYENFGNSFMVPVDAPNPYRSENCLCVQNILKLMQEKETGLNVFLLDMCRKRNDYDDTIPILDALKVTANIVFGYATCQGAEAFEIQHSGLANGIFMKFLKDRLLEDKKITVLLDEVAEDMGKCHLTKGKQALEIRSSLSEKRALTDPIQGTEYSAESLVRNLQWAKAHELPESMCLKFDCGVQIQLGFAAEFSNVMIIYTSIVYKPPEIIMCDAYVTDFPLDLDIDPKDANKGTPEETGSYLVSKDLPKHCLYTRLSSLQKLKEHLVFTVCLSYQYSGLEDTVEDKQEVNVGKPLIAKLDMHRGLGRKTCFQTCLMSNGPYQSSAATSGGAGHYHSLQDPFHGVYHSHPGNPSNVTPADSCHCSRTPDAFISSFAHHASCHFSRSNVPVETTDEIPFSFSDRLRISEK

Storage and Stability:
Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: PE conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Note: Applications are based on unconjugated antibody.